Current Report Filing (8-k)
January 10 2022 - 07:05AM
Edgar (US Regulatory)
false 0001294133 0001294133 2022-01-10
2022-01-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): January 10,
2022
INOGEN, INC.
(Exact name of Registrant as Specified in Its Charter)
|
Delaware
|
001-36309
|
33-0989359
|
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
301 Coromar Drive,
Goleta, CA
|
|
93117
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s Telephone Number, Including Area Code: (805)
562-0500
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common Stock, $0.001 par value
|
|
INGN
|
|
The NASDAQ Stock Market LLC
(NASDAQ Global Select Market)
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
|
Item 2.02.
|
Results of Operations and Financial Condition.
|
On January 10, 2022, Inogen, Inc. (the “Company”) issued a press
release reporting preliminary, unaudited revenue results for the
fourth quarter and full year ended December 31, 2021 and announcing
operational updates. A copy of the press release is furnished
herewith as Exhibit 99.1 to this Current Report 8-K.
|
Item
7.01.
|
Regulation FD Disclosure.
|
Investor Conference
The chief executive officer and chief
financial officer of the Company will participate in the 2022 J.P.
Morgan Healthcare Conference, which begins on Monday, January 10,
2022 at 8:00 a.m. PT. The chief executive officer and chief
financial officer are scheduled to present at the conference on
Wednesday, January 12, 2022 at 7:30 a.m. PT. During the conference
and in separate sessions with analysts and investors, the Company’s
officers will refer to an updated slide presentation. A copy of
this updated slide presentation is attached hereto as Exhibit 99.2
and is incorporated herein by reference. Included in this updated
slide presentation is an updated inside sales representative
headcount of 292 as of December 31, 2021. Interested parties can
access the live audio webcast of this conference presentation from
the Events section of the Investor Relations page on the Company’s
website at www.inogen.com.
The information furnished pursuant to this Current Report on Form
8-K, including Exhibit 99.1 and 99.2 attached hereto, shall not be
deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise
subject to the liabilities of that section, nor shall it be deemed
incorporated by reference into any other filing under the
Securities Act of 1933, as amended (the “Securities Act”) or the
Exchange Act, except as expressly set forth by specific reference
in such a filing.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
INOGEN, INC.
|
|
|
|
|
|
Date: January 10, 2022
|
By:
|
/s/ Jason Somer
|
|
|
|
Jason Somer
Executive Vice President, General Counsel, Secretary
|
Inogen (NASDAQ:INGN)
Historical Stock Chart
From Jul 2022 to Aug 2022
Inogen (NASDAQ:INGN)
Historical Stock Chart
From Aug 2021 to Aug 2022
